Xu Cong Claire: insider trades.
Xu Cong Claire reported 4 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 2 sales ($7K), across 1 company.
- Transactions
- 4
- Purchases (P)
- 0
- Sales (S)
- 2
- Companies
- 1
- Name as filed
- Xu Cong Claire
Companies
| Company | Relationship | Transactions |
|---|---|---|
| NovaBridge Biosciences (NBP) | Officer · EVP, Clinical Development | 4 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-31 | NovaBridge Biosciences | S | 3,282 | $0.79 | 304,201 | Form 4 |
| 2026-08-30 | NovaBridge Biosciences | M | 9,382 | — | 307,483 | Form 4 |
| 2026-07-06 | NovaBridge Biosciences | S | 4,485 | $0.89 | 298,101 | Form 4 |
| 2026-07-04 | NovaBridge Biosciences | M | 12,432 | — | 302,586 | Form 4 |
Questions
What stock did Xu Cong Claire buy or sell?
Xu Cong Claire reported 4 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 2 sales ($7K), across 1 company.
Is Xu Cong Claire the same person as other filers with this name?
This page covers SEC CIK 2114309 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/xu-cong-claire-2114309.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.